摘要
目的:探讨CD40和Id4在前列腺癌中的表达及意义。方法:应用免疫组化技术,选取71例前列腺癌、40例高级别前列腺内瘤病(HGPIN)及30例前列腺增生症(BPH)标本,检测CD40和Id4在上述组织中的表达差异。结果:71例前列腺癌标本中,CD40总体阳性表达率达67.6%,且以阳性和强阳性表达为主,阳性表达率显著高于其它两组,差异有统计学意义(P<0.05)。前列腺癌组,CD40蛋白阳性表达率随病理组织学分级的升高而升高,在高分化、中分化及低分化期依次是28.6%、68.0%、74.4%,高分化组与其他两组比较差异有统计学意义(P均<0.05);三组中Id4因子阳性表达率呈逐渐下降趋势,前列腺癌组Id4阳性表达率与HGPIN组、BPH组两组间分别比较,均有显著差异(P<0.05)。在前列腺癌病理分级中,Id4因子阳性表达率随肿瘤病理分级的增高而增加,分别为高分化57.1%、中分化68.0%、低分化76.9%,但三组间进行统计学比较无显著差异(P>0.05)。结论:CD40、Id4二者的异常表达在前列腺癌生物学行为中可能起着重要作用,可为将来前列腺癌的生物免疫治疗及基因治疗研究提供新的选择。
Objective：To investigate the expression and significance of CIM0 and Id4 in human prostate cancer （PCa）. Methods： CD40 and Id4 expression in paraffin embedded tissue of human prostate cancer（ n = 71 ）, high grade prostatic intraepithelial neoplasia （ HGPIN, n = 40 ） and benign prostatic hyperplasia （ BPH, n = 30 ） were investigated by immunohistoehemical method. Results ：The expression level of CD40 in prostate cancer tissue was higher than those in the HGPIN and BHP tissue. The positive rate in PCa tissue was 67.6%. the difference was significant statistically（P 〈 0.05）. In PCa tissue, the expression level of CD40 in well -differentiated tissue was 28.6%,in moderately differentiated and poorly differentiated tissue was 68.0% and 74.4%, the expression level grows by the grade of hierarchical pathology. The difference can been seen in the well differentiated group between other groups（P 〈 0.05 ）. The positive expression rate of Id4 was descending gradually in the three groups, the positive expression rate of Id4 in human prostate cancer was different to those in HGIN and BPH （P 〈 0.05 ）. In grading human prostate caneer, the positive expression rate of Id4 growing gradually with the heighten of pathologic grading of cancer, in well - differentiated tissue was 57.1% ,in moderately differentiated and poorly differentiated tissue was 68.0% and 76.9%, without difference in the three groups（ P 〉 0.05 ）. Conclusion： The abnormal expression of CD40 and Id4 in human prostate cancer tissue have a significant effect, which may be provide a new option for human prostate cancer immune therapy and gene therapy.
出处
《现代肿瘤医学》
CAS
2016年第1期100-104,共5页
Journal of Modern Oncology
